Baird raised the firm’s price target on Praxis Precision (PRAX) to $433 from $275 and keeps an Outperform rating on the shares. The firm raised its target as two NDA submissions kick off the FDA review process.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $305 from $282 at Wells Fargo
- Praxis Therapeutics: Advancing Late-Stage Neurology Pipeline Toward Commercialization with Multibillion-Dollar Market Potential
- Praxis Precision Medicines: NDA Progress, Robust Pipeline, and Strong Cash Runway Support Buy Rating
- Praxis Precision reports Q4 EPS ($3.50), consensu ($3.13)
- Praxis Precision sees cash runway into 2028